{"id":516040,"date":"2021-07-21T16:38:21","date_gmt":"2021-07-21T20:38:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/"},"modified":"2021-07-21T16:38:21","modified_gmt":"2021-07-21T20:38:21","slug":"alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/","title":{"rendered":"Alector to Present New Data from Frontotemporal Dementia and Alzheimer\u2019s Disease Programs at the 2021 Alzheimer\u2019s Association International Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRN<br \/><\/em><br \/>\n        <em>Company to Host Analyst and Investor Conference Call on July 29 at 1:00 p.m. ET<\/em>\n      <\/p>\n<p>SOUTH SAN FRANCISCO, Calif., July  21, 2021  (GLOBE NEWSWIRE) &#8212; Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at the upcoming 2021 Alzheimer\u2019s Association International Conference being held July 26-30, 2021 virtually and in Denver, Colorado.<\/p>\n<p>Among the data being presented at the conference will be six- and twelve-month data from the open-label Phase 2 INFRONT-2 study evaluating AL001 in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-<em>GRN<\/em>). Alector plans to host a conference call to review the AL001 Phase 2 results on July 29 at 1:00 p.m. ET.<\/p>\n<p>Alector will also present two posters related to its AL002 Alzheimer\u2019s disease (AD) program. The first poster will include the results of the AL002 Phase 1 study in healthy volunteers and the second poster will highlight the study design of the ongoing INVOKE-2 trial in people with early AD.<\/p>\n<p>\n        <strong>Oral Presentation for AL001 Phase 2 Data<\/strong>\n      <\/p>\n<p>\n        <strong>Presentation Title<\/strong>: Six Months Interim Analysis of the Phase 2 Study of AL001 in Frontotemporal Dementia Patients Carrying a Granulin Mutation (#54593)<br \/><strong>Session Name<\/strong>: Human: A potpourri of human clinical trials <br \/><strong>Presenter<\/strong>: Robert Paul, M.D., Ph.D., Chief Medical Officer, Alector <br \/><strong>Session Date and Time<\/strong>: Thursday, July 29, 2021 at 10 a.m. ET<\/p>\n<p>\n        <strong>Poster Presentations for AL002<\/strong><br \/>\n        <br \/>Poster presentations will be available for on-demand viewing beginning on Monday, July 26.<\/p>\n<p>\n        <strong>Poster Title<\/strong>: INVOKE-2 \u2013 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL002 in Participants with Early Alzheimer\u2019s Disease (#54615) <br \/><strong>Presenting Author<\/strong>: Robert Paul, M.D., Ph.D., Chief Medical Officer, Alector<\/p>\n<p>\n        <strong>Poster Title<\/strong>: A Phase 1 Study of AL002 in Healthy Volunteers (#54669)<br \/><strong>Presenting Author<\/strong>: Mike Ward, Ph.D., Senior Director, Clinical Science, Alector<\/p>\n<p>\n        <strong>Alector AL001 Conference Call Information<\/strong><br \/>\n        <br \/>Alector management will host a conference call at 1:00 p.m. ET. Analysts and investors are invited to participate in the conference call by dialing (888) 705-0365 from the\u00a0U.S.\u00a0and\u00a0Canada\u00a0or (415) 817-9241 internationally and using the conference ID 5267479. The live webcast can be accessed on the investor page of Alector\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hW4i6tpfHfry6V5vLY7sBsMTom3LVtDPI3EpTVJs06N7QclWuVznu6ZLIIwKOnq2jS-945b1rJo4EjzodYeNVc7sVmxaJn_oA-JWjC1u3Mk=\" rel=\"nofollow noopener\" target=\"_blank\">investors.alector.com<\/a>. A replay of the webcast will be available on Alector\u2019s website approximately two hours after the completion of the event and will be archived for up to 30 days.<\/p>\n<p>\n        <strong>About\u00a0Alector<\/strong><br \/>\n        <br \/>Alector\u00a0is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company\u00a0is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain\u2019s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies.\u00a0Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.\u00a0The Company\u2019s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer\u2019s disease. This scientific approach is also the basis for the Company\u2019s immuno-oncology programs.\u00a0Alector\u00a0is headquartered in\u00a0South\u00a0San Francisco,\u00a0California. For additional information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3NGHUuRLIFOIEgwANgewz-vS8Zqaw3jfQdTeY2s6NaMb-p-PEih7JjJC-GEH-I5e6RIGkhnbBYMG2VEBfqZwng==\" rel=\"nofollow noopener\" target=\"_blank\">www.alector.com<\/a>.<\/p>\n<p>\n        <strong>Alector Contacts:<\/strong>\n      <\/p>\n<p>Michelle Corral<br \/>VP, Communications and Investor Relations<br \/>650-808-7016<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=furptW9OwIXfaqDkXYLWqXcbRzEaMSRh5mBqXSGsrQsF0RcMoTEAE8TsaP2SaubA9LVR0ko9GpxTCIOtmzkEoOPDcLelw7skmlWYU9FivuNInIRNoWCo8mdmEZsiiOh-\" rel=\"nofollow noopener\" target=\"_blank\">michelle.corral@alector.com<\/a><\/p>\n<p>1AB<br \/>Dan Budwick<br \/>973-271-6085<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JTcXvBVVfGZ68M2JsAbthHoa_bH4hpJOC15n7dSJZEPNrg4oL8WPPjUl3EzBj2pLZypfF0FsHQ8W92r6-rrnWg==\" rel=\"nofollow noopener\" target=\"_blank\">dan@1abmedia.com<\/a><\/p>\n<p>Investors:<br \/>Alector, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=e1HuJkz3tuQBj7CS_Nni1rFmdcfeWhXppCOikxZTnCGcDV1wJRy-kGToj1OBB3C9dvNCzPry5aCuxW4NO30fQQ==\" rel=\"nofollow noopener\" target=\"_blank\">ir@alector.com<\/a><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDYxMiM0MzA4Njc2IzIxMjQ5OTA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/b326f745-1459-47cb-be2b-2131192edf37\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRN Company to Host Analyst and Investor Conference Call on July 29 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif., July 21, 2021 (GLOBE NEWSWIRE) &#8212; Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at the upcoming 2021 Alzheimer\u2019s Association International Conference being held July 26-30, 2021 virtually and in Denver, Colorado. Among the data being presented at the conference will be six- and twelve-month data from the open-label Phase 2 INFRONT-2 study evaluating AL001 in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). Alector plans to host a conference call to review the AL001 Phase 2 results &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alector to Present New Data from Frontotemporal Dementia and Alzheimer\u2019s Disease Programs at the 2021 Alzheimer\u2019s Association International Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-516040","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alector to Present New Data from Frontotemporal Dementia and Alzheimer\u2019s Disease Programs at the 2021 Alzheimer\u2019s Association International Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alector to Present New Data from Frontotemporal Dementia and Alzheimer\u2019s Disease Programs at the 2021 Alzheimer\u2019s Association International Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRN Company to Host Analyst and Investor Conference Call on July 29 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif., July 21, 2021 (GLOBE NEWSWIRE) &#8212; Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at the upcoming 2021 Alzheimer\u2019s Association International Conference being held July 26-30, 2021 virtually and in Denver, Colorado. Among the data being presented at the conference will be six- and twelve-month data from the open-label Phase 2 INFRONT-2 study evaluating AL001 in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). Alector plans to host a conference call to review the AL001 Phase 2 results &hellip; Continue reading &quot;Alector to Present New Data from Frontotemporal Dementia and Alzheimer\u2019s Disease Programs at the 2021 Alzheimer\u2019s Association International Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-21T20:38:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDYxMiM0MzA4Njc2IzIxMjQ5OTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alector to Present New Data from Frontotemporal Dementia and Alzheimer\u2019s Disease Programs at the 2021 Alzheimer\u2019s Association International Conference\",\"datePublished\":\"2021-07-21T20:38:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\\\/\"},\"wordCount\":564,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDYxMiM0MzA4Njc2IzIxMjQ5OTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\\\/\",\"name\":\"Alector to Present New Data from Frontotemporal Dementia and Alzheimer\u2019s Disease Programs at the 2021 Alzheimer\u2019s Association International Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDYxMiM0MzA4Njc2IzIxMjQ5OTA=\",\"datePublished\":\"2021-07-21T20:38:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDYxMiM0MzA4Njc2IzIxMjQ5OTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDYxMiM0MzA4Njc2IzIxMjQ5OTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alector to Present New Data from Frontotemporal Dementia and Alzheimer\u2019s Disease Programs at the 2021 Alzheimer\u2019s Association International Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alector to Present New Data from Frontotemporal Dementia and Alzheimer\u2019s Disease Programs at the 2021 Alzheimer\u2019s Association International Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/","og_locale":"en_US","og_type":"article","og_title":"Alector to Present New Data from Frontotemporal Dementia and Alzheimer\u2019s Disease Programs at the 2021 Alzheimer\u2019s Association International Conference - Market Newsdesk","og_description":"Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRN Company to Host Analyst and Investor Conference Call on July 29 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif., July 21, 2021 (GLOBE NEWSWIRE) &#8212; Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at the upcoming 2021 Alzheimer\u2019s Association International Conference being held July 26-30, 2021 virtually and in Denver, Colorado. Among the data being presented at the conference will be six- and twelve-month data from the open-label Phase 2 INFRONT-2 study evaluating AL001 in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). Alector plans to host a conference call to review the AL001 Phase 2 results &hellip; Continue reading \"Alector to Present New Data from Frontotemporal Dementia and Alzheimer\u2019s Disease Programs at the 2021 Alzheimer\u2019s Association International Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-21T20:38:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDYxMiM0MzA4Njc2IzIxMjQ5OTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alector to Present New Data from Frontotemporal Dementia and Alzheimer\u2019s Disease Programs at the 2021 Alzheimer\u2019s Association International Conference","datePublished":"2021-07-21T20:38:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/"},"wordCount":564,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDYxMiM0MzA4Njc2IzIxMjQ5OTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/","name":"Alector to Present New Data from Frontotemporal Dementia and Alzheimer\u2019s Disease Programs at the 2021 Alzheimer\u2019s Association International Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDYxMiM0MzA4Njc2IzIxMjQ5OTA=","datePublished":"2021-07-21T20:38:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDYxMiM0MzA4Njc2IzIxMjQ5OTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDYxMiM0MzA4Njc2IzIxMjQ5OTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease-programs-at-the-2021-alzheimers-association-international-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alector to Present New Data from Frontotemporal Dementia and Alzheimer\u2019s Disease Programs at the 2021 Alzheimer\u2019s Association International Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=516040"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516040\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=516040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=516040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=516040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}